MD Anderson and Summit Therapeutics Announce Strategic Collaboration to Accelerate Development of Ivonescimab
July 26, 2024
July 26, 2024
HOUSTON, Texas, July 26 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 25, 2024:
* * *
Five-year collaboration intended to advance PD-1/VEGF bispecific in several solid tumors across multiple clinical trials
* * *
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating t . . .
* * *
Five-year collaboration intended to advance PD-1/VEGF bispecific in several solid tumors across multiple clinical trials
* * *
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating t . . .